Alector, Inc.
ALEC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001653087
In the last 90 days, Alector, Inc. insiders filed 0 open-market purchases and 3 sales; 140 institutions reported holding it in 13F filings for Q2 2026, worth $183.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alector, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $296.1K in total
- Insiders trading
- 3
- Net value
- −$296.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alector, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wong-Sarad Grace | Principal Accounting Officer | 106,015 | Sep 4, 2026 | 11 |
| Berkley Neil Lindsay | CFO & Chief Business Officer | 350,649 | Sep 4, 2026 | 6 |
| Rosenthal Arnon | Chief Executive Officer | 2,294,600 | Sep 4, 2026 | 7 |
| Desouza Errol B | Director | 98,650 | Jun 17, 2026 | 1 |
| Lavigne Louis J Jr | Director | 128,109 | Jun 17, 2026 | 1 |
| Scheller Richard H | Director | 134,899 | Jun 17, 2026 | 2 |
| Altmeyer Mark | Director | 98,650 | Jun 17, 2026 | 1 |
| Yaffe Kristine | Director | 124,109 | Jun 17, 2026 | 1 |
| Hammond Paula | Director | 103,609 | Jun 17, 2026 | 1 |
| Garofalo Elizabeth A. | Director | 118,650 | Jun 17, 2026 | 1 |
| Kenkare-Mitra Sara | President and Head of R&D | 501,652 | Dec 3, 2025 | 1 |
| Grasso Marc | Chief Financial Officer | 296,072 | Jun 4, 2025 | 0 |
| Romano Gary | Chief Medical Officer | 332,977 | Mar 5, 2025 | 0 |
| Wehner David M. | Director | 115,330 | Jun 12, 2024 | 0 |
| Polaris Venture Partners VI, L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners Founders' Fund VI, L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Management Co. VI, L.L.C. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners VI (AIV), L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners VI (AIV-B), L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| McGuire Terrance | Director, 10% Owner | 10,853,817Indirect | Sep 13, 2023 | 0 |
| Gerngross Tillman U. | Director | 2,644,319 | Jun 15, 2023 | 0 |
| King Robert | Chief Development Officer | 550,871 | Oct 4, 2022 | 0 |
| Suliman Shehnaaz | President and COO | 102,598 | Dec 14, 2021 | 0 |
| Paul Robert | Chief Medical Officer | 234,319 | Aug 11, 2021 | 0 |
| Yu Calvin | Vice President, Finance | 76,686 | Jul 7, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)5:45 PM ET | Sep 2-4 | 2 days | Wong-Sarad GracePrincipal Accounting Officer | SSale | −9.45K | $2.61 | −$24.7K | −8.2%106.0K after | 3 lots |
| Sep 4, 2026 (view filing)5:45 PM ET | Sep 3 | 1 day | Berkley Neil LindsayCFO & Chief Business Officer | SSale | −29.3K | $2.66 | −$77.9K | −7.7%350.6K after | |
| Sep 4, 2026 (view filing)5:45 PM ET | Sep 3 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −72.6K | $2.66 | −$193.5K | −3.1%2.29M after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −87.2K | $1.97 | −$171.8K | −3.6%2.37M after | |
| Jun 3, 2026 (view filing) | Jun 2-3 | 1 day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −9.18K | $1.94 | −$17.8K | −8.8%95.5K after | 2 lots |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Berkley Neil LindsayCFO & Chief Business Officer | SSale | −19.4K | $1.97 | −$38.1K | −4.8%379.9K after | |
| Apr 17, 2026 (view filing) | Apr 16 | 1 day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −1.82K | $2.65 | −$4.82K | −1.7%104.6K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 10 | 2 days | Wong-Sarad GracePrincipal Accounting Officer | SSale | −1.00K | $2.65 | −$2.65K | −0.9%106.5K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Berkley Neil LindsayCFO & Chief Business Officer | SSale | −29.6K | $2.12 | −$62.9K | −7.9%344.7K after | |
| Mar 3, 2026 (view filing) | Mar 3 | Same day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −3.37K | $2.08 | −$7.00K | −3.0%107.5K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −8.07K | $2.12 | −$17.1K | −6.8%110.8K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −81.9K | $2.12 | −$173.6K | −3.4%2.34M after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −4.08K | $2.50 | −$10.2K | −3.3%118.9K after | 10b5-1 |
| Dec 8, 2025 (view filing) | Dec 5 | 3 days | Wong-Sarad GracePrincipal Accounting Officer | SSale | −4.75K | $1.21 | −$5.75K | −3.7%123.0K after | |
| Dec 3, 2025 (view filing) | Dec 3 | Same day | Berkley Neil LindsayChief Bus Ofcr & Interim CFO | SSale | −37.3K | $1.12 | −$41.7K | −9.1%374.3K after | |
| Dec 3, 2025 (view filing) | Dec 3 | Same day | Wong-Sarad GracePrincipal Accounting Officer | SSale | −8.06K | $1.12 | −$9.02K | −5.9%127.7K after | |
| Dec 3, 2025 (view filing) | Dec 3 | Same day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −41.7K | $1.12 | −$46.7K | −7.7%501.7K after | |
| Dec 3, 2025 (view filing) | Dec 3 | Same day | Rosenthal ArnonChief Executive Officer | SSale | −104.3K | $1.12 | −$116.9K | −4.1%2.42M after | |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Wong-Sarad GracePrincipal Accounting Officer | SSale | −5.91K | $2.50 | −$14.8K | −5.4%103.4K after | |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Berkley Neil LindsayPrincipal Financial Officer | SSale | −15.8K | $2.50 | −$39.6K | −4.4%346.6K after | |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −23.6K | $2.50 | −$59.1K | −4.2%543.3K after | |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −51.6K | $2.50 | −$128.9K | −2.1%2.35M after | |
| Aug 27, 2025 (view filing) | Aug 26 | 1 day | Hammond PaulaDirector | SSale | −14.0K | $2.36 | −$33.0K | −15.7%74.9K after | 10b5-1 |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Yaffe KristineDirector | SSale | −1.00K | $1.44 | −$1.44K | −1.0%95.4K after | 10b5-1 |
| Jun 4, 2025 (view filing) | Jun 2 | 2 days | Grasso MarcChief Financial Officer | SSale | −16.5K | $1.34 | −$22.1K | −5.3%296.1K after | |
| Jun 4, 2025 (view filing) | Jun 2 | 2 days | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −23.9K | $1.34 | −$32.0K | −4.5%512.3K after | |
| Jun 4, 2025 (view filing) | Jun 2 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −52.1K | $1.34 | −$69.8K | −2.1%2.41M after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Grasso MarcChief Financial Officer | SSale | −18.1K | $1.47 | −$26.6K | −5.5%312.6K after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −29.1K | $1.47 | −$42.7K | −5.1%536.1K after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −40.3K | $1.47 | −$59.3K | −1.6%2.47M after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Romano GaryChief Medical Officer | SSale | −16.3K | $1.47 | −$24.0K | −4.7%333.0K after | |
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Grasso MarcChief Financial Officer | SSale | −16.5K | $2.52 | −$41.6K | −4.7%330.7K after | |
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −52.2K | $2.52 | −$131.5K | −2.0%2.51M after | |
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −26.5K | $2.52 | −$66.8K | −4.5%565.2K after | |
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Romano GaryChief Medical Officer | SSale | −14.9K | $2.52 | −$37.5K | −4.1%349.3K after | |
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Grasso MarcChief Financial Officer | SSale | −7.30K | $4.88 | −$35.6K | −5.3%130.7K after | |
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −26.5K | $4.88 | −$129.3K | −1.3%1.95M after | |
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −13.9K | $4.88 | −$68.0K | −4.6%291.7K after | |
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Romano GaryChief Medical Officer | SSale | −8.48K | $4.88 | −$41.4K | −4.5%179.8K after | |
| Aug 23, 2024 (view filing) | Aug 22 | 1 day | Scheller Richard HDirector | SSale | −44.3K | $5.16 | −$228.3K | −55.8%35.0K after | |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Hammond PaulaDirector | SSale | −10.5K | $5.06 | −$53.1K | −14.8%60.2K after | 10b5-1 |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Yaffe KristineDirector | SSale | −5.00K | $5.06 | −$25.3K | −6.9%67.7K after | 10b5-1 |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −25.1K | $4.80 | −$120.6K | −1.3%1.98M after | |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Romano GaryChief Medical Officer | SSale | −8.04K | $4.80 | −$38.6K | −4.1%188.3K after | |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −13.2K | $4.80 | −$63.4K | −4.1%305.6K after | |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Grasso MarcChief Financial Officer | SSale | −6.92K | $4.80 | −$33.2K | −4.8%138.0K after | |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Romano GaryChief Medical Officer | SSale | −6.00K | $6.92 | −$41.5K | −3.0%196.3K after | |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −10.2K | $6.92 | −$70.4K | −3.1%318.8K after | |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Grasso MarcChief Financial Officer | SSale | −5.72K | $6.92 | −$39.6K | −3.8%145.0K after | |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −18.8K | $6.92 | −$130.4K | −0.9%2.00M after |